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Abstract
Dengue infections pose a huge burden to health care providers in most tropical countries. Careful
clinical examination and history-taking supplemented by newer rapid diagnostic tests may lead to
early etiological diagnosis. For severe dengue, early recognition of vascular permeability followed by
rapid physiological replacement of fluids is life-saving. Prognosis of patients depends upon optimum
management, an outcome that requires preparation via organization, training, and use of evidence-
based practice guidelines.
Introduction and context
The world is in the grip of a dengue pandemic heralded
in 1977 by the emergence of each of the four dengue
viruses from Asia to the Americas [1]. Until this
pandemic is controlled, millions of patients with acute
dengue illnesses will require diagnosis and treatment
each year. Dengue viruses, members of the Flavivirus
genus, are transmitted in an urban cycle, the virus
traveling from viremic humans to mosquitoes (usually
Aedes aegypti) and then to susceptible humans, generat-
ing a complex of syndromes – most of which are benign
and short-lived but some with a fatal outcome – that is
uniquely treatable. Prognosis is determined by an ill-
understood combination of viral, immunological, and
host factors, all of which begin with the sudden onset of
high fever. There are no early signs that make it possible
to predict severe outcomes, which only appear late and
are accompanied by defervescence. It is critical that
physicians who monitor dengue illnesses stay alert to the
onset of the unique syndrome: dengue vasculopathy
(dengue hemorrhagic fever [DHF]/dengue shock syn-
drome [DSS]). With the onset of this syndrome,
prognosis rests squarely in the hands and prepared
mind of the physician. Here, we will describe clinical
features of severe dengue syndromes and outline
treatment options where these are known to affect
outcome.
Recent advances
Each of the four dengue viruses produces an acute febrile
exanthema, which in its classic form (dengue fever)
presents with an acute onset of fever, sometimes with
shaking chills, and often with a retro-orbital headache.
The disease may exhibit an early macular blush,
conjunctival injection, myalgia, inappetence (including
taste aberrations), upper respiratory signs, gastro-
intestinal disturbances, and prostration. Patients often
complain of the severity of their illness; prostration and
weakness may extend well into convalescence. During
infection, dengue viruses infect liver parenchyma and
cells of the reticuloendothelial system. The febrile period
lasts 4 or 5 days and is followed by defervescence and
often a maculopapular generalized body rash. At
defervescence, the disease will reveal its severe or
relatively benign nature.
Severe dengue
Severe dengue is heralded by persistent vomiting, severe
abdominal pain, extreme lethargy/weakness, mucosal
bleeding, and (as a result of rapid plasma leakage) a
rapid rise in hematocrit (HCT). Recognition of these
warning signs should alert a prepared and rehearsed
treatment team. In children, the predominant presenta-
tion often consists of a history of several days of fever
with sudden signs of blood volume loss, tachycardia,
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capillary filling, and decreased urine output. This state
may progress to cyanosis, confusion, lethargy, and frank
hypotension. The underlying mechanism is a rapid
opening of putative ‘capillary pores’ that leak fluid and,
in more severe cases, smaller proteins such as albumin
into interstitial spaces. From this point onwards, patients
who do not receive prompt intravenous fluid therapy
may progress rapidly to a shock state, the outcome of
which is time-sensitive. It is critical to recognize that
shock presents as a continuum progressing from mild to
moderate and severe hemodynamic instability. In the
early phase of shock, the systolic blood pressure is
maintained at the expense of increasing tachycardia and
peripheral vasoconstriction, a state known as compen-
sated shock. In dengue, this is manifested by narrow
pulse pressure (less than 20 mm Hg); a systolic
hypotension portends decompensation and an immi-
nent total cardio-respiratory collapse [2]. Laboratory
tests usually document a leucopenia characterized by
neutropenia, mild to moderate elevations in liver
enzyme blood values, and mild to moderate thrombo-
cytopenia. Laboratory results do not accurately predict
the hemorrhagic diathesis that often accompanies
dengue infection; menstruating women may suffer
menometrorrhagia, and individuals with peptic ulcer
disease may experience a severe and potentially fatal
gastrointestinal hemorrhage [3,4].
Management strategy
There are many parameters that can be deranged in
severe dengue: thrombocytopenia, coagulopthy, hyper-
glycemia, liver enzymes, and multi-organ failure, all of
which can distract the doctor’s attention. In modern
medicine, specialists may be called in for organ manage-
ment: an anaesthetist for respiratory distress, a hepato-
logist for raised liver enzymes, a nephrologist for no
urine output, a renologist for metabolic acidosis, a
gastroenterologist for gastrointestinal bleeding, a neu-
rologist for seizures, a hematologist for low platelets and
coagulation defects, an endocrinologist for hypergly-
cemia, and a cardiologist for hypotension. The reason for
multi-organ involvement is mainly (but not wholly)
hypoperfusion. Specialty consults must not distract the
physician in charge from focusing on one thing and only
one thing: achieving and maintaining hemodynamic
stability by fluid, colloid, or blood administration
(without overloading the patient with too much fluid)
until he or she is out of the critical period. All other
clinical issues should await achievement of hemody-
namic stability. Although patients with vascular perme-
ability are resuscitated as if they have diarrhea, a more
apt therapeutic analogy may be a burn injury or
hypovolemia from ‘third space’ loss in surgery [5].
Treatment of dengue vasculopathy
Successful management of dengue vasculopathy relies on
meticulous regulation of parenteral fluids and colloid
during the period of increased vascular leakage, together
with proactive management of major bleeding should
this develop [6,7]. The physician should remember that
in a ‘leaky’ capillary scenario, beyond a certain hydro-
static pressure, the faster the fluids are infused, the faster
they leak into the ‘third space’, and that all fluid
administered will be reabsorbed and fluid overload
may result. Although vascular permeability is often
thought to characterize severe dengue infections in
children, it also occurs in adults [8]. Studies have
shown that children are at higher risk than adults for
developing vascular permeability during secondary
dengue infections [9]. Placing the microHCT centrifuge
on the ward for use by trained nurses facilitates the use
of HCT determinations to manage fluid requirements
and administration. Careful clinical research has pro-
vided invaluable data on which to base management
guidelines [10-15].
From a double-blind randomized comparison of three
fluids for initial resuscitation of 383 Vietnamese children
with dengue shock, it was demonstrated that Ringer’s
lactate solution is sufficient to resuscitate children with
moderately severe DSS [15]. However, should the disease
proceed to severe shock, administration of dextran 70 or
6% hydoxyethyl starch will stabilize vascular volume and
blood pressure in most cases. Given adverse reactions
associated with the use of dextran, starch may be
preferable for this group, although dextran 1 can be
administered immediately before dextran 40 or 70,
acting as a hapten inhibitor that blocks molecules of
dextran 40 or 70 from forming toxic immune complexes
[16]. A randomized controlled trial in children with
dengue shock showed that aggressive intravenous fluid
resuscitation in the first hour achieved 100% survival
regardless of what fluid was pushed. Over 95% of these
patients were recognized to have shock before hypoten-
sion was recorded [17]. Unnecessary treatments are in
wide use. Steroids are still prescribed for patients with
dengue diseases, as are other unproven expensive and
high-risk interventions, such as platelet concentrates, AC-
17 (carbazochrome sodium sulfonate), and aggregated
gamma globulin [18-21].
Bleeding
Bleeding is a frequent cause of severe dengue illness,
especially in adults. Here, the physician must distinguish
between bleeding complicating hypovolemia from
unrecognized vascular permeability and that from focal
hemorrhaging (for example, in peptic ulcer disease) [4].
Severe but occult bleeding can be difficult to recognize.
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but with a relatively normal HCT compared with those
with only plasma leakage (39.5% versus 45%, P = 0.032)
[22]. Many patients with severe bleeding have initial or
ongoing plasma leakage that keeps the HCT in the
normal range despite the severe bleed. Importantly, the
administration of blood products such as platelets and
fresh frozen plasma to treat patients with threatened
blood loss does not hold up to careful scrutiny [22].
Complications
Chronic diseases, particularly in older patients, interact
with dengue infections producing a stormy course and,
in some cases, a fatal outcome. Deaths have been
reported in older patients experiencing primary dengue
infections. Risk factors for fatal outcome in adults
include diabetes, chronic obstructive pulmonary disease,
renal failure, and cardiovascular disease [23,24].
Implications for clinical practice
The requirement for acute and rapid fluid repletion
together with possible blood loss makes for a volatile
mix, and in the absence of competent emergency and
critical care, too many patients have been lost to dengue
shock due to hemorrhagic or multi-organ failure compli-
cations. In recent decades and certainly since 1988,
aggressive efforts by clinical leaders in major Southeast
Asian countries have brought about a transformation of
treatment protocols for DHF/DSS, with a corresponding
drop in case fatality rates [15,17,19,25,26]. A correspond-
ing effort to organize and train physicians in emergency
and critical care practices of dengue will be required in the
Americas.
Fortunately, many if not most patients with dengue
infections experience a rapid onset of high fever and seek
treatment early. For those patients presenting within the
first two days of onset of fever, new rapid tests that detect
dengue viral RNA or a dengue NS1 (nonstructural
protein 1) circulating in blood together with a platelet
count may make it possible to identify an ongoing acute
dengue illness in the clinic [27,28]. Such tests will be
available only for a minority of dengue patients. Despite
an etiological diagnosis, the physician must still decide
which patients have or will soon develop vascular
leakage. There is some evidence that gall bladder
sonograms may reveal gall bladder wall thickening as
an early predictor of dengue vasculopathy [29]. In the
absence of this facility, performing a full blood count in
the early febrile phase of dengue may be cost-effective.
While a drop in total white blood cell count may be the
first indicator of a dengue infection, an accompanying
early assessment of the HCT provides a reference for
comparisons of HCT and detection and fluid
management of plasma leakage during the defervescent
and critical phases [27].
The majority of dengue cases recover with or without
treatment; therefore, the challenge to the clinician is to
identify the minority who could progress to severe
disease and may die without appropriate interventions
after the first few days of fever. In this regard, the critical
role that primary health care plays in triage and gate-
keeping cannot be overemphasized. As suggested by the
World Health Organization Collaborating Center for the
Management of DHF in Bangkok, Thailand, clinicians at
the front line need to identify the sick patients in need of
admission [30]. Adequate oral fluid intake has been
shown to reduce the risk of hospitalization for dengue
fever and prevent the in-hospital services from being
overwhelmed by patients admitted for monitoring for
signs of clinical deterioration [31].
It is the authors’ experience that primary care facilities
in Asia and tropical regions of the Americas are
understaffed, under-resourced, and (particularly in the
Americas) unprepared to deliver adequate diagnostic
or supportive care to dengue patients. It is likely that
this results in over-hospitalization. In addition to the
need to strengthen diagnostic and treatment abilities of
frontline as well as reference center staff, most countries
will benefit from organization of a national post-
graduate training program similar to the one in Vietnam.
Experience has shown that careful triage of out-patients,
use of a short-term holding and treatment facility, and
an admission strategy that admits only sick patients for
the shortest period of time during the critical period
provide the best possible prognosis to dengue patients.
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